Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Utrecht – page 46

625 clinical trials in Utrecht, The Netherlands across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Utrecht at a glance
625
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

625 trials in Utrecht

Open in trial search

Pyruvate kinase deficiency anaemia

Not recruiting

Study on the Effectiveness and Safety of Mitapivat in Children with Pyruvate Kinase Deficiency Not Receiving Regular Blood Transfusions

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Malignant melanoma stage III

Not recruiting

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Spinal muscular atrophy

Not recruiting

Study of Taldefgrobep Alfa for Patients with Spinal Muscular Atrophy on Stable Nusinersen and/or Risdiplam Regimen or with Onasemnogene Abeparvovec-xioi History

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Taldefgrobep Alfa
  • Sponsor:Biohaven Pharmaceuticals Inc.

Non-small cell lung cancer

Not recruiting

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Primary immunodeficiency syndrome+2

Not recruiting

Study on the Effect of Human Normal Immunoglobulin on Lung Disease in Patients with Primary Antibody Deficiency

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Universitair Medisch Centrum Utrecht

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Glioma

Not recruiting

Study of Vorasidenib for Patients with Residual or Recurrent Grade 2 Glioma with IDH1 or IDH2 Mutation

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Not recruiting
Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Pneumonia+2

Not recruiting

Study on Aspirin and Pantoprazole for Reducing Heart Attack Risk in Hospitalized Pneumonia Patients

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Amsterdam UMC Stichting

Adenocarcinoma of colon

Not recruiting

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Utrecht

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on TTR amyloidosis and heart disease treatments, investigating new therapeutic approaches for cardiac conditions. Clinical trials evaluate novel medications for improving patient mobility and cardiac function.

  • Heart Disease Management
  • Cardiac Biomarkers
  • Treatment Efficacy

Research aims to enhance quality of life for patients with hereditary and wild-type ATTR cardiomyopathy.

02 Cancer Research

Comprehensive studies in gastric cancer, bladder cancer, and neuroblastoma, exploring innovative treatment combinations and diagnostic methods.

  • Immunotherapy Applications
  • Targeted Therapies
  • Diagnostic Imaging

Advanced trials combining established treatments with novel approaches to improve patient outcomes.

03 Neurological Disorders

Groundbreaking research in Amyotrophic Lateral Sclerosis and chronic inflammatory conditions, focusing on innovative treatments and disease modification strategies.

  • Gene-Targeted Therapies
  • Neurological Function
  • Disease Progression

Studies aim to develop effective treatments for rare and challenging neurological conditions.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.